Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

about

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

Item

http://www.wikidata.org/entity/Q43716462

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@en

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@nl

type

Item

label

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@en

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@nl

prefLabel

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@en

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@nl

P1476

Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.

@en

P2093

Bing Feng

http://www.w3.org/2001/XMLSchema#string

Chen Wang

http://www.w3.org/2001/XMLSchema#string

Shaobo Chen

http://www.w3.org/2001/XMLSchema#string

Yuzhou Guan

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Proteasome inhibitors in lung cancer.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms.

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells.

Proteasome inhibitor, bortezomib, for myeloma and lymphoma.

P304

325-328

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MUS.24122

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24464710

http://www.w3.org/2001/XMLSchema#string